bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) was up 7.4% during trading on Wednesday . The company traded as high as $8.17 and last traded at $7.07. Approximately 684,447 shares changed hands during trading, a decline of 89% from the average daily volume of 6,303,871 shares. The stock had previously closed at $6.58.
Analyst Ratings Changes
A number of research analysts have recently commented on BLUE shares. Wedbush dropped their price target on bluebird bio from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 10th. Morgan Stanley decreased their price objective on bluebird bio to $3.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 17th. Raymond James upgraded bluebird bio from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Finally, Barclays upgraded bluebird bio from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $3.00 to $5.00 in a research note on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, bluebird bio presently has a consensus rating of “Hold” and an average target price of $10.50.
bluebird bio Stock Performance
The firm has a market capitalization of $546.01 million, a PE ratio of -0.87 and a beta of 1.29. The stock’s 50-day simple moving average is $4.66 and its 200-day simple moving average is $4.72.
Insider Buying and Selling at bluebird bio
In other bluebird bio news, CEO Andrew Obenshain sold 21,805 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jason Cole sold 7,448 shares of bluebird bio stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $32,696.72. Following the transaction, the insider now owns 203,740 shares in the company, valued at approximately $894,418.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Obenshain sold 21,805 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the sale, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,364 shares of company stock worth $146,664. Company insiders own 2.90% of the company’s stock.
Institutional Trading of bluebird bio
Hedge funds have recently bought and sold shares of the stock. Amalgamated Bank bought a new stake in shares of bluebird bio in the 1st quarter worth about $39,000. PEAK6 Investments LLC bought a new stake in shares of bluebird bio in the 2nd quarter worth about $41,000. US Bancorp DE grew its holdings in bluebird bio by 82.9% during the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 3,847 shares during the last quarter. Keybank National Association OH bought a new position in bluebird bio during the 2nd quarter valued at about $42,000. Finally, Laurion Capital Management LP bought a new position in bluebird bio during the 2nd quarter valued at about $42,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- Lowe’s Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.